Compare ALM & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALM | AMRX |
|---|---|---|
| Founded | N/A | 2002 |
| Country | United States | United States |
| Employees | 342 | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.0B |
| IPO Year | N/A | 2018 |
| Metric | ALM | AMRX |
|---|---|---|
| Price | $14.89 | $17.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $22.33 | $15.60 |
| AVG Volume (30 Days) | ★ 4.9M | 2.1M |
| Earning Date | 05-20-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 157.89 |
| EPS | N/A | ★ 0.19 |
| Revenue | N/A | N/A |
| Revenue This Year | $817.94 | $4.48 |
| Revenue Next Year | $158.05 | $7.13 |
| P/E Ratio | ★ N/A | $89.53 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.16 | $7.67 |
| 52 Week High | $24.41 | $17.86 |
| Indicator | ALM | AMRX |
|---|---|---|
| Relative Strength Index (RSI) | 41.56 | 71.87 |
| Support Level | $14.70 | $12.46 |
| Resistance Level | $20.59 | $17.86 |
| Average True Range (ATR) | 1.23 | 0.55 |
| MACD | -0.05 | -0.12 |
| Stochastic Oscillator | 18.74 | 66.58 |
Almonty Industries Inc is engaged in the development of the Sangdong Mine in South Korea, and the Company is currently mining, processing, and shipping tungsten concentrate from the Panasqueira tin and tungsten mine in Covilha, Castelo Branco, Portugal (Panasqueira Mine). Additionally, the Company is evaluating its molybdenum project with inferred mineral resources on a separate property adjacent to the tungsten orebody at the Sangdong Mine, its Valtreixal tin and tungsten mine project located in Western Spain in the province of Zamora (Valtreixal Mine), and the newly-acquired Gentung Browns Lake tungsten project located in Montana, USA (Gentung-Browns Lake Project). The company has two geographical locations: the Iberian Peninsula (Spain and Portugal) and the Republic of Korea.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.